首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1407337

组织工程和再生市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品、应用、地区和竞争细分

Tissue Engineering and Regeneration Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, by Application, by region, and Competition

出版日期: 2023年11月07日 | 出版商:

TechSci Research | 英文 170 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2022 年，全球组织工程和再生市场价值为 145.7 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2028 年复合CAGR为8.35%。组织工程和再生是生物医学科学和工程领域，专注于开发生物替代品来修復或取代人体受损或患病的组织和器官。这些领域旨在恢復正常组织功能、促进康復并提高患有各种疾病的患者的生活品质。组织工程是利用细胞、生物材料和生化因子的组合来创建功能性活组织或器官的科学和实践。组织工程的主要目标是设计和建造能够复製天然组织和器官的结构和功能的生物替代品。在组织工程的背景下，再生是恢復体内受损或流失的组织和器官的过程。这是一种自然的生物反应，但在组织工程和再生医学的背景下，它通常涉及在医疗干预的帮助下增强人体的自然再生能力。

全球人口正在老化，导致与年龄相关的疾病和退化性疾病的盛行率更高。组织工程和再生疗法为与年龄相关的组织损伤和器官衰竭提供了潜在的解决方案。用于移植的捐赠器官严重短缺。组织工程可望创造实验室培养的器官和组织，减少对捐赠器官的依赖。干细胞研究的进展，包括对多能干细胞和诱导多能干细胞（iPSC）的了解，扩大了组织再生和个人化医疗的可能性。生物列印、基因编辑（例如 CRISPR-Cas9）和生物材料的创新推动了组织工程领域的发展，使其更加可行和有效。医疗保健专业人员和患者越来越意识到再生疗法及其潜在益处，从而推动了再生疗法的接受和采用。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	145.7亿美元
2028 年市场规模	234亿美元
2023-2028 年CAGR	8.35%
成长最快的细分市场	细胞疗法
最大的市场	北美洲

器官移植需求旺盛

器官发生公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
Acelity 有限合伙公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
齐默比美特控股公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
史赛克公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
Integra生命科学控股公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
美敦力公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
施乐辉公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
阿瑟西斯公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
维瑞塞尔公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
欧西里斯治疗公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis

第 17 章：策略建议

第 18 章：关于我们与免责声明

简介目录

Product Code: 20609

Global Tissue Engineering and Regeneration Market has valued at USD 14.57 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.35% through 2028. Tissue Engineering and Regeneration are fields of biomedical science and engineering that focus on the development of biological substitutes to repair or replace damaged or diseased tissues and organs in the human body. These fields aim to restore normal tissue function, promote healing, and improve the quality of life for patients suffering from a wide range of medical conditions. Tissue engineering is the science and practice of creating functional and living tissues or organs using a combination of cells, biomaterials, and biochemical factors. The primary goal of tissue engineering is to design and construct biological substitutes that can replicate the structure and function of natural tissues and organs. Regeneration, in the context of tissue engineering, is the process of restoring damaged or lost tissues and organs in the body. It is a natural biological response, but in the context of tissue engineering and regenerative medicine, it often involves enhancing the body's natural regenerative abilities with the help of medical interventions.

The global population is aging, leading to a higher prevalence of age-related diseases and degenerative conditions. Tissue engineering and regenerative therapies offer potential solutions for age-related tissue damage and organ failure. There is a significant shortage of donor organs for transplantation. Tissue engineering holds the promise of creating lab-grown organs and tissues, reducing the dependence on donor organs. Progress in stem cell research, including the understanding of pluripotent stem cells and induced pluripotent stem cells (iPSCs), has expanded the possibilities for tissue regeneration and personalized medicine. Innovations in bioprinting, gene editing (e.g., CRISPR-Cas9), and biomaterials have advanced the field of tissue engineering, making it more viable and effective. Healthcare professionals and patients are becoming more aware of regenerative therapies and their potential benefits, driving acceptance and adoption.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 14.57 Billion
Market Size 2028	USD 23.40 Billion
CAGR 2023-2028	8.35%
Fastest Growing Segment	Cell Therapy
Largest Market	North America

High Demand for Organ Transplants

The demand for organ transplants far exceeds the supply of available donor organs. This shortage of organs for transplantation has led to long waiting lists, and many patients may not receive a transplant in time. Tissue engineering offers a potential solution to address this organ shortage by creating lab-grown organs and tissues. Tissue engineering and regenerative medicine techniques involve growing functional organs and tissues in the laboratory using a patient's cells or other biocompatible materials. This approach provides an alternative source of organs for transplantation, reducing the dependence on donor organs. Tissue engineering allows for the creation of personalized organs that can be tailored to individual patients. This reduces the risk of organ rejection and the need for long-term immunosuppressive medications, which are necessary in traditional organ transplantation. Tissue engineering can create organs that are traditionally challenging to obtain from donors, such as vascularized organs, like hearts and kidneys. This expands the range of available organs for transplantation.

Tissue-engineered organs have the potential to significantly reduce the waiting times for organ transplantation, increasing the chances of successful treatment for patients in need. Tissue-engineered organs can be designed with enhanced functionality, potentially outperforming natural organs in certain aspects. For example, engineered organs can be optimized for specific tasks, such as drug metabolism or tissue repair. Tissue engineering techniques can ensure better compatibility between the transplanted organ and the recipient's immune system. This reduces the risk of graft rejection and complications. Tissue engineering eliminates ethical concerns associated with organ trafficking and illegal organ trade. It also reduces the reliance on a complex and sometimes unreliable supply chain for donor organs. The demand for tissue-engineered organs has driven significant research and innovation in the field of regenerative medicine. Scientists are continually working to improve the techniques for growing functional organs and tissues. This factor will help in the development of the Global Tissue Engineering and Regeneration Market.

Advancements in Stem Cell Research

Stem cells are undifferentiated cells with the unique ability to differentiate into various cell types, making them a crucial component in regenerative medicine. Pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), are versatile and can differentiate into almost any cell type in the body. iPSCs are generated by reprogramming adult cells, making them a valuable resource for regenerative medicine research. Researchers have made significant progress in developing methods to guide the differentiation of stem cells into specific cell types, tissues, and organs. This directed differentiation is essential for producing functional tissues and organs for transplantation. Advances in 3D bioprinting technology enable the precise deposition of stem cells and biomaterials to create complex, three-dimensional structures. This technology has the potential to produce functional tissues and organs layer by layer. Researchers have developed techniques to create organoids, which are miniaturized, simplified versions of organs. Organoids can be derived from stem cells and serve as valuable models for studying tissue development and disease, as well as for drug testing. The emergence of gene editing tools like CRISPR-Cas9 has facilitated the modification of stem cells for specific purposes. Researchers can edit the genes of stem cells to enhance their regenerative potential or correct genetic defects before differentiation.

Exosomes, small vesicles secreted by stem cells, contain bioactive molecules that can influence tissue repair and regeneration. Stem cell-derived exosomes are being explored as a regenerative therapy without the need for direct cell transplantation. Researchers have successfully created functional organoids like mini-brains and mini-kidneys from stem cells. These organoids provide insights into organ development, disease mechanisms, and drug screening. The establishment of stem cell banks for different cell types has made it easier to access standardized and quality-controlled stem cell lines for research and clinical applications. Stem cell-based therapies are advancing in clinical trials and treatment settings. For example, mesenchymal stem cells are being used in orthopedics and tissue repair, while hematopoietic stem cell transplantation remains a standard treatment for certain blood-related disorders. Regulatory agencies are developing guidelines for the use of stem cell-based products and therapies to ensure their safety and efficacy. This regulatory clarity is essential for advancing stem cell therapies toward mainstream medical practice. Stem cells, especially iPSCs, have enabled the creation of disease-specific cell lines for studying the mechanisms of various diseases and screening potential drug candidates. This factor will pace up the demand of the Global Tissue Engineering and Regeneration Market.

Increasing Aging Population

As people age, they are more prone to degenerative diseases, such as osteoarthritis, Alzheimer's disease, cardiovascular disease, and age-related macular degeneration. These conditions often involve tissue and organ damage, making regenerative therapies a potential solution to address age-related health issues. Elderly individuals are more susceptible to chronic wounds, including pressure ulcers and diabetic foot ulcers. Regenerative approaches, such as advanced wound care and skin tissue engineering, play a critical role in wound healing and reducing complications in the aging population. The elderly frequently experience musculoskeletal problems, such as fractures, joint pain, and reduced mobility. Tissue engineering can offer solutions to repair or replace damaged bone and cartilage, promoting functional recovery and an improved quality of life. Aging is a major risk factor for cardiovascular diseases, which can lead to heart muscle damage. Regenerative therapies aim to repair damaged cardiac tissue, potentially improving heart function and extending the lives of older individuals. Age is a significant risk factor for neurodegenerative diseases, such as Alzheimer's and Parkinson's. Stem cell-based regenerative approaches hold promise for neural repair and the potential to slow the progression of these conditions.

Aging is associated with changes in the immune system, which can impact wound healing, tissue repair, and overall health. Regenerative approaches aim to enhance the body's ability to repair and regenerate tissues. Advancements in biomaterials have led to the development of implants and scaffolds that can be used in joint replacements, cardiovascular procedures, and tissue reconstruction, providing better options for elderly patients. Regenerative medicine can be tailored to individual patients, accounting for their unique health conditions and needs, which is particularly important for the aging population. Regenerative therapies offer the potential to enhance the quality of life for older individuals by addressing age-related health challenges and improving their overall well-being. As life expectancy continues to rise, there is a growing desire among the elderly to maintain an active and independent lifestyle. Regenerative medicine can support this by addressing age-related health issues and promoting healthy aging. Effective regenerative therapies can reduce the long-term healthcare costs associated with age-related diseases by addressing the root causes and potentially reducing the need for chronic medications and repeat surgeries. The increasing aging population has spurred research and development efforts in regenerative medicine to address the unique health needs of older individuals. This factor will accelerate the demand of the Global Tissue Engineering and Regeneration Market

Key Market Challenges

Long and Expensive Development Process

The development of regenerative therapies begins with extensive research and preclinical testing to understand the safety and efficacy of the proposed treatments. This stage can take many years and involve substantial financial resources. Clinical trials are a critical step in the development process to demonstrate the safety and effectiveness of regenerative therapies in humans. Conducting these trials involves a substantial investment, takes several years, and requires compliance with stringent regulatory requirements. Obtaining regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a lengthy and costly process. Companies must meet rigorous standards and provide comprehensive data to prove the safety and efficacy of their therapies. Transitioning from small-scale laboratory production to large-scale manufacturing can be challenging. Ensuring consistent and cost-effective production of regenerative therapies is a complex task. Maintaining quality control and standardization throughout the manufacturing process is crucial. Deviations can lead to product inconsistency and may pose risks to patient safety. The development of regenerative therapies requires substantial financial resources, including funding for research, clinical trials, manufacturing facilities, and regulatory compliance. Raising this capital can be a barrier to entry for startups and smaller companies. Many regenerative therapies do not successfully make it to market. The high failure rate in clinical trials and the lengthy timelines contribute to the overall cost of development. The long development process can result in market uncertainties. By the time a therapy reaches the market, changes in the competitive landscape or evolving clinical standards can impact its commercial success.

Immunological Compatibility

When foreign tissues or engineered organs are transplanted into a patient, there is a risk of immune rejection. The recipient's immune system may recognize the transplanted tissue as foreign and mount an immune response to destroy it. To mitigate the risk of rejection, patients often need to take immunosuppressive drugs. These medications suppress the immune system to prevent it from attacking the transplanted tissue. However, long-term use of immunosuppressants can have side effects and increase the patient's susceptibility to infections and other health issues. In some cases, immunological incompatibility can lead to host vs. graft disease, where the recipient's immune system aggressively attacks the transplanted tissue, leading to graft failure. Allogeneic therapies, which involve using donor tissues or cells, often face immunological compatibility challenges. Finding a suitable donor with a closely matched immune profile can be difficult, and even with a close match, immune responses can occur. Achieving immunological compatibility is a key aspect of personalized medicine in regenerative therapies. Tailoring treatments to an individual's immune system requires extensive research and understanding of the patient's immune profile. Even with immunosuppression, the host vs. graft reaction can still occur. This reaction can lead to tissue damage and, in some cases, graft failure. Some tissue engineering and regenerative medicine strategies aim to develop strategies that do not rely on donor tissues or cells, thus bypassing immunological compatibility issues. This includes using the patient's own cells (autologous therapies) or universal donor cells.

Key Market Trends

Personalized Medicine

issue engineering and regenerative medicine aim to create therapies that are customized to each patient's unique needs. This approach can address individual variations in health, genetics, and disease. Induced pluripotent stem cells (iPSCs) are reprogrammed from a patient's own cells and can be used to generate patient-specific tissues and organs. This minimizes the risk of immune rejection and graft-versus-host disease. Advancements in genomics and molecular profiling allow for a detailed analysis of a patient's genetic and molecular characteristics. This information is used to guide treatment decisions and tailor regenerative therapies. iPSCs and patient-derived cells are used to create disease models, enabling researchers to study diseases in a patient-specific context. This is valuable for understanding disease mechanisms and testing potential treatments. Personalized regenerative therapies reduce the risk of immune rejection, as they are based on the patient's own cells. This minimizes the need for immunosuppressive drugs. By understanding a patient's genetic and molecular profile, clinicians can optimize the choice of tissue engineering and regenerative therapies. This ensures that the treatment is more likely to be effective and safe for the individual patient. Personalized medicine allows clinicians to predict a patient's response to specific therapies, helping to select the most appropriate regenerative approach for a better outcome. Personalized medicine places the patient at the center of care, emphasizing tailored treatments that consider the patient's unique biology, preferences, and needs. In some cases, companion diagnostics are used to identify the most suitable regenerative therapy for a patient based on their genetic or molecular profile.

Segmental Insights

Product Insights

In 2022, the Global Tissue Engineering and Regeneration Market largest share was held by Tissue Engineering segment and is predicted to continue expanding over the coming years. Tissue engineering encompasses a wide range of applications, including the regeneration of skin, bone, cartilage, blood vessels, and various other tissues and organs. This versatility allows it to address a diverse set of medical needs, making it a significant component of the market. There is a growing clinical demand for tissue engineering solutions, particularly in areas like wound care, orthopaedics, and cardiovascular surgery. These clinical needs drive the market share for tissue engineering products. Advancements in materials science and biomaterials have enabled the development of scaffolds and matrices that closely mimic the natural environment of tissues. These advanced materials enhance tissue engineering techniques and contribute to their widespread use. Tissue engineering offers regenerative solutions for a wide variety of patients, including those with chronic wounds, orthopedic injuries, and tissue defects resulting from trauma or surgery. The potential to restore function and improve quality of life drives the demand for tissue engineering approaches. Tissue engineering is a highly active area of research and innovation. Researchers and companies continuously explore new techniques, materials, and technologies to improve the effectiveness of tissue engineering solutions, driving market growth.

Application Insights

In 2022, the Global Tissue Engineering and Regeneration Market largest share was held by orthopaedics segment and is predicted to continue expanding over the coming years. Orthopedic conditions, such as osteoarthritis, sports injuries, and age-related degenerative disorders, are widespread, affecting a large population of patients worldwide. These conditions often require surgical interventions or regenerative therapies, making the orthopaedics' segment a significant part of the market. The global population is aging, and elderly individuals are more prone to orthopedic issues, including joint problems and fractures. This demographic shift has increased the demand for orthopedic regenerative solutions. Joint replacement surgeries, such as hip and knee replacements, are common orthopedic procedures. Regenerative medicine approaches, including tissue engineering, are increasingly used to enhance the outcomes of these surgeries and promote faster recovery. Tissue engineering and regenerative medicine offer the potential to regenerate damaged or degenerated bone and cartilage, which are central to orthopedic health. This regenerative potential is highly relevant to the orthopaedics field. Patients with orthopedic conditions often experience pain and reduced mobility. Regenerative therapies can alleviate pain, improve joint function, and enhance the quality of life for these patients.

Regional Insights

The North America region dominates the Global Tissue Engineering and Regeneration Market in 2022. North America, particularly the United States and Canada, has well-developed and advanced healthcare infrastructure. This includes state-of-the-art hospitals, research facilities, and a strong medical device industry, providing a conducive environment for tissue engineering and regenerative medicine. North America is home to many world-renowned universities and research institutions, which conduct cutting-edge research in the field of tissue engineering and regenerative medicine. These institutions often collaborate with the private sector, fostering innovation and development. The region hosts a significant biotechnology and pharmaceutical industry, with numerous companies engaged in the development and commercialization of regenerative therapies. This industry's presence contributes to advancements in the field. Government agencies, such as the National Institutes of Health (NIH) in the United States, provide substantial funding for research in regenerative medicine. This financial support helps drive innovation and the development of new therapies. North America has a well-established regulatory framework for medical products, including regenerative therapies. The U.S. Food and Drug Administration (FDA) plays a pivotal role in overseeing the approval and commercialization of these therapies, which often start with clinical trials in the region.

Key Market Players

Organogenesis Inc.

Acelity L.P. Inc.

Zimmer Biomet Holdings Inc.

Stryker Corporation

Integra LifeSciences Holdings Corporation

Medtronic plc

Smith & Nephew plc

Athersys Inc.

Vericel Corporation

Osiris Therapeutics, Inc.

Report Scope:

In this report, the Global Tissue Engineering and Regeneration Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue Engineering and Regeneration Market, By Product:

Biomaterials
Cell Therapy
Tissue Engineering

Tissue Engineering and Regeneration Market, By Application:

Orthopedics
Dermatology
Cardiology
Neurology
Others

Tissue Engineering and Regeneration Market, By region:

North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tissue Engineering and Regeneration Market.

Available Customizations:

Global Tissue Engineering and Regeneration Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue Engineering and Regeneration Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Biomaterials, Cell Therapy, Tissue Engineering)
- 5.2.2. By Application (Orthopedics, Dermatology, Cardiology, Neurology, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Market Map

6. Asia Pacific Tissue Engineering and Regeneration Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Tissue Engineering and Regeneration Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Application
- 6.3.2. India Tissue Engineering and Regeneration Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Application
- 6.3.3. Australia Tissue Engineering and Regeneration Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Application
- 6.3.4. Japan Tissue Engineering and Regeneration Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Product
    - 6.3.4.2.2. By Application
- 6.3.5. South Korea Tissue Engineering and Regeneration Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Product
    - 6.3.5.2.2. By Application

7. Europe Tissue Engineering and Regeneration Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Tissue Engineering and Regeneration Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Application
- 7.3.2. Germany Tissue Engineering and Regeneration Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Application
- 7.3.3. Spain Tissue Engineering and Regeneration Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Tissue Engineering and Regeneration Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Application
- 7.3.5. United Kingdom Tissue Engineering and Regeneration Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Application

8. North America Tissue Engineering and Regeneration Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Tissue Engineering and Regeneration Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Application
- 8.3.2. Mexico Tissue Engineering and Regeneration Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Application
- 8.3.3. Canada Tissue Engineering and Regeneration Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Application

9. South America Tissue Engineering and Regeneration Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Tissue Engineering and Regeneration Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Tissue Engineering and Regeneration Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Tissue Engineering and Regeneration Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Application

10. Middle East and Africa Tissue Engineering and Regeneration Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Tissue Engineering and Regeneration Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Tissue Engineering and Regeneration Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Tissue Engineering and Regeneration Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Tissue Engineering and Regeneration Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Organogenesis Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
16.2. Acelity L.P. Inc
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
16.3. Zimmer Biomet Holdings Inc.
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
16.4. Stryker Corporation
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
16.5. Integra LifeSciences Holdings Corporation
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
16.6. Medtronic plc
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
16.7. Smith & Nephew plc
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
16.8. Athersys Inc.
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
16.9. Vericel Corporation
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
16.10. Osiris Therapeutics, Inc.
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis